At the AAPM, four abstract presentations focused on Proxcelan with Cesium-131 and its radiobiological characteristics and related dosimetric outcomes in treatment planning.
Proxcelan from IsoRay Medical is the newest isotope used in low dose (LDR) brachytherapy for the treatment of prostate cancer.
The four abstracts included:
1. “Cesium-131 Prostate Brachytherapy and Treatment Plan Parameters”
Authors: Sutlief, S. & Wallner, K
2. “Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy”
Author: Musmacher, J.
3. “Determination of TG-43 Parameters for Cs-131 Model CS-1R2 Seed Using Radiochromic EBT Film Dosimetry”
Author: Chiu-Tsau, S.
4. “Dosimetric Characterization of Model CS-1 Cesium-131 Source by Thermoluminescence Dosimetry in Liquid Water”
Author: Tailor, R. & Ibbott, G